A placebo-controlled pharmacodynamic and pharmacokinetic interaction study between tamsulosin and acenocoumarol

Br J Clin Pharmacol. 2003 Mar;55(3):314-6. doi: 10.1046/j.1365-2125.2003.01793.x.

Abstract

Aim: To evaluate pharmacokinetic and pharmacodynamic interactions between tamsulosin and acenocoumarol.

Methods: Twelve healthy volunteers received tamsulosin 0.4 mg or placebo once daily for 9 days in a double-blind, cross-over study. On day 5 of each study period, a single 10-mg oral dose of racemic acenocoumarol was administered.

Results: The ratios (point estimates (90% confidence intervals)) of values in the presence and absence of tamsulosin were: AUCPT 1.01 (0.98, 1.03); maximum prothrombin time (Ptmax) 0.99 (0.94, 1.05); AUC (R)-acenocoumarol 1.02 (0.90, 1.16), and AUC (S)-acenocoumarol 1.03 (0.89, 1.20). Both combinations, tamsulosin and placebo with acenocoumarol, were well-tolerated.

Conclusions: Multiple doses of tamsulosin had no effect on the pharmacokinetics or pharmacodynamics of a single high dose of acenocoumarol.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acenocoumarol / pharmacokinetics*
  • Acenocoumarol / pharmacology
  • Administration, Oral
  • Adolescent
  • Adrenergic alpha-Antagonists / pharmacology*
  • Adult
  • Anticoagulants / pharmacokinetics*
  • Chromatography, High Pressure Liquid
  • Cross-Over Studies
  • Double-Blind Method
  • Drug Interactions
  • Humans
  • Male
  • Prothrombin Time
  • Sulfonamides / pharmacology*
  • Tamsulosin

Substances

  • Adrenergic alpha-Antagonists
  • Anticoagulants
  • Sulfonamides
  • Tamsulosin
  • Acenocoumarol